Related Experiment Video
Updated: Mar 27, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
MiR-125b Functions as a Tumor Suppressor and Enhances Chemosensitivity to Cisplatin in Osteosarcoma
Fei Wang1, Dapeng Yu2, Zhen Liu3
1Department of Trauma and Orthopedics, Institute of Chinese People's Liberation Army, General Hospital of Jinan Military Command, Jinan, China wangfeicz@126.com.
Abstract:
MicroRNAs are highly conserved noncoding RNA that negatively modulate protein expression at a posttranscriptional and/or translational level and are deeply involved in the pathogenesis of several types of cancers. To date, the potential microRNAs regulating the growth and progression of osteosarcoma are not fully identified yet. Previous reports have shown differentially expressed miR-125b in osteosarcoma. However, the role of miR-125b in human osteosarcoma has not been totally illuminated. In this study, we have shown that miR-125b was downregulated in human osteosarcoma tissues compared to the adjacent tissues and effects as a tumor suppressor in vitro We found that stable overexpression of miR-125b in osteosarcoma cell lines U2OS and MG-63 inhibited cell proliferation, migration, and invasion. Our data also verified that Bcl-2 is the target of miR-125b. Meanwhile, we showed that Bcl-2 was inversely correlated with miR-125b in osteosarcoma tissues. More importantly, we proved that miR-125b increased the chemosensitivity of osteosarcoma cell lines to cisplatin by targeting Bcl-2. In conclusion, our data demonstrate that miR-125b is a tumor suppressor and support its potential application for the treatment of osteosarcoma in the future.
Insights
MicroRNA 125b (miR-125b) acts as a tumor suppressor in osteosarcoma. Its downregulation promotes cancer growth, but restoring miR-125b levels inhibits proliferation and enhances chemosensitivity to cisplatin.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- MicroRNAs regulate gene expression and are implicated in cancer pathogenesis.
- The specific role of microRNA 125b (miR-125b) in osteosarcoma progression remains unclear.
- Previous studies suggest differential expression of miR-125b in osteosarcoma.
Purpose of the Study:
- To investigate the function of miR-125b in human osteosarcoma.
- To determine if miR-125b acts as a tumor suppressor in osteosarcoma.
- To explore the therapeutic potential of miR-125b in osteosarcoma treatment.
Main Methods:
- Quantitative analysis of miR-125b expression in osteosarcoma tissues versus adjacent tissues.
- Stable overexpression of miR-125b in U2OS and MG-63 osteosarcoma cell lines.
- Assessment of cell proliferation, migration, and invasion assays.
- Validation of Bcl-2 as a direct target of miR-125b.
- Evaluation of miR-125b's effect on chemosensitivity to cisplatin.
Main Results:
- miR-125b was significantly downregulated in osteosarcoma tissues.
- Overexpression of miR-125b suppressed osteosarcoma cell proliferation, migration, and invasion in vitro.
- Bcl-2 was identified as a direct target of miR-125b, with inverse correlation observed in patient tissues.
- miR-125b enhanced the sensitivity of osteosarcoma cells to cisplatin treatment by targeting Bcl-2.
Conclusions:
- miR-125b functions as a tumor suppressor in human osteosarcoma.
- Targeting Bcl-2, miR-125b exhibits potential as a therapeutic agent for osteosarcoma.
- Restoring miR-125b levels may offer a novel strategy for osteosarcoma treatment.
